FDA Faulted for Inappropriate Collaboration With Drug Company Before Approving Alzheimer's Drug

Name: FDA Faulted for Inappropriate Collaboration With Drug Company Before Approving Alzheimer's Drug
Uploaded: 2023-01-06T20:41:28+00:00
Duration: P114S
Description: • After major pushback, the FDA approved Biogen&apos;s $56,000 drug, Aduhelm, in 2021.

Credit: Rumble

Duration: 01:54s 06 Jan 2023 0 shares 1 views

FDA Faulted for Inappropriate Collaboration With Drug Company Before Approving Alzheimer's Drug

• After major pushback, the FDA approved Biogen's $56,000 drug, Aduhelm, in 2021.

FDA Faulted for Inappropriate Collaboration With Drug Company Before Approving Alzheimer's Drug

You might like